Company Filing History:
2 out of 3 
2 out of 13 
1 out of 3 Years Active: 2018-2023
Title: Huiping Gao: Innovator in Cellular Immunotherapy
Introduction
Huiping Gao is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of cellular immunotherapy. With a total of five patents to his name, Gao has been at the forefront of developing innovative methods for treating solid tumors.
Latest Patents
Among his latest patents, one notable invention is focused on compositions and methods of cellular immunotherapy. This patent discloses methods for treating subjects exhibiting solid tumors that express Glypican-3 (GPC3). The methods typically utilize GPC3 chimeric antigen receptor immunoresponsive cells to effectively target and kill tumor cells. Another significant patent involves an anti-CD19 humanized antibody, which is prepared from a murine monoclonal antibody. This invention includes a chimeric antigen receptor containing the humanized antibody and an immune cell expressing it. The humanized antibody demonstrates better affinity than murine antibodies and has excellent activity and safety, providing a new means for treating CD19-expressing tumors.
Career Highlights
Huiping Gao has worked with notable companies in the biotechnology sector, including Carsgen Therapeutics Limited and Crage Medical Co., Limited. His work in these organizations has contributed to advancements in cancer treatment and immunotherapy.
Collaborations
Gao has collaborated with esteemed colleagues in his field, including Zonghai Li and Hua Jiang, who have also made significant contributions to the development of innovative therapies.
Conclusion
Huiping Gao's work in cellular immunotherapy exemplifies the impact of innovation in the medical field. His patents and collaborations highlight his commitment to advancing cancer treatment through groundbreaking research and development.